Lifeboat Foundation

He uses infrared lasers, cryotherapy machines, and a lot of stem cells.

We have launched a new webinar series featuring discussion panels with the researchers + Q&A session for patrons. The first episode hosted by Dr. Oliver Medvedik will feature Dr. Aubrey de Grey, Dr. Matthew O’Connor, Michael Rae, and Dr. Amutha Boominathan from the SENS Research Foundation.

If you are a Lifespan Hero you can join us live for the show and get access to the recording for a few months before the public release.

Our work is largely supported by the generosity of our monthly patrons, the Lifespan Heroes, and this year, we will be showing our appreciation for that support with the launch of a brand new initiative – our new webinar series where you can meet the scientists working on the solutions to aging and age-related diseases.

Continue reading “Announcing a New Webinar Series – MitoSENS” »

From the article:

In recent years, a growing number of scientific studies have backed an alarming hypothesis: Alzheimer’s disease isn’t just a disease, it’s an infection.

While the exact mechanisms of this infection are something researchers are still trying to isolate, a litany of papers argue the deadly spread of Alzheimer’s goes way beyond what we used to think.

Continue reading “The Cause of Alzheimer’s Could Be Coming From Inside Your Mouth, Study Claims” »

Trying to streamline an operation that spends more than $5 billion a year on developing new drugs, Novartis dispatched teams to jetmaker Boeing Co. and Swissgrid AG, a power company, to observe how they use technology-laden crisis centers to prevent failures and blackouts. That led to the design of something that looks like the pharma version of NASA’s Mission Control: a global surveillance hub where supercomputers map and chart Novartis’s network of 500 drug studies in 70 countries, trying to predict potential problems on a minute-by-minute basis.

A third of development costs comes from clinical trials. Novartis wants to make them cheaper and faster.

Buried deep within the DNA of Asian individuals is a genetic clue pointing to the existence of an unknown human ancestor. Remarkably, it wasn’t a human who reached this startling conjecture, but rather an artificially intelligent algorithm. Welcome to archaeology in the 21st century.

New research published last week in Nature Communications suggests a yet-to-be discovered hominid interbred with modern humans tens of thousands of years ago. This mystery species eventually went extinct, but an AI developed by researchers from the Institute of Evolutionary Biology (IBE) and several other European institutions found traces of its existence in the DNA of present-day people with Asian ancestry. A press release issued by the Centre for Genomic Regulation said it’s the first time deep learning has been used to explain human history, “paving the way for this technology to be applied in other questions in biology, genomics and evolution.”

Fatima Ali, who was voted “Fan Favorite” on Season 15 of “Top Chef,” lost her battle with a rare bone and soft tissue cancer Friday. She was just 29.

Well…

(you thought).

A study of thousands of human genomes reveals where mutations happen most often when our parents’ genes combine.

Continue reading “Genetic Mutations In Our Bodies Might Be Less Random Than We Thought, Scientists Say” »

The monkeys exhibited anxiety, depression, and schizophrenia-like behaviors.

Metastasis is the leading cause of death from cancer, occurring when cancer cells separate from the original tumor to proliferate elsewhere. These new cancer cells travel through the bloodstream or lymphatic system. Since these bodily systems are thoroughly connected, cancer can spread to a variety of locations. Breast cancer, for example, “tends to spread to the bones, liver, lungs, chest wall, and brain.”

Cancer cell plasticity — an ability that allows cancer cells to shift physiological characteristics dramatically — fosters metastasis and is responsible for cancer’s resistance to treatments. To combat its resistance, researchers at the University of Basel in Switzerland decided to turn cancer’s cellular plasticity against itself. They used Rosiglitazone, an anti-diabetic drug, along with MEK inhibitors in mice implanted with breast cancer cells. Their aim was to alter the cancer cells.

The drug combination hijacked the breast cancer cells during epithelial-mesenchymal transition (EMT), a process by which the cells undergo biochemical changes. EMT plays a role in many bodily functions, such as tissue repair. In unaltered cancer cells, EMT allows them to migrate away from the original tumor while maintaining their oncogenic properties.